Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB, abbreviated as IBT, is a Swedish clinical-stage biopharmaceutical company focused on developing pharmaceutical drugs targeting diseases affecting premature infants. The company utilizes its specialized microbiological research platform to develop biotherapeutic products, prominently featuring IBP-94, an investigational drug designed to prevent necrotizing enterocolitis, a devastating and life-threatening disease affecting preterm infants. Its core business activities encompass microbiological research, clinical trial advancement, biopharmaceutical drug design, and regulatory compliance. As a clinical-stage research firm, the company generates minimal commercial revenue and finances its drug development pipeline through equity capital market offerings. Infant Bacterial Therapeutics holds a pioneering position in neonatology pharmaceutical research. The company is headquartered in Stockholm, Sweden, and its B shares trade on Nasdaq Stockholm.
2 of the funds FundTelligence covers report a position in Infant Bacterial Therapeutics.
- Legal name
- Infant Bacterial Therapeutics AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 2
Funds holding Infant Bacterial Therapeutics
- Storebrand Sverige Småbolag Plus — Storebrand · 0.03 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.01 % (full portfolio disclosed, October 2026)